

Research and Reviews:Journal of Medical and Health Sciences

Breast Cancer Awareness

Mamatha M

Department of Pharmacology, Teegala Ram Reddy College, JNT University, India

Research Article

Received:23/07/2016
Accepted:23/07/2016
Published:23/07/2016

*For Correspondence

Corresponding author affiliation.
Masters of pharmacy, Department
of pharmacology, Tee gala Ram
Reddy College, JNTU University

E-Mail:mmamathabpharm@gmail.com

Keywords:Breast Cancer, Danger,
Mammogram.

ABSTRACT

Every year in the United States, more than 200,000 ladies get breast growth and more than 40,000 ladies bite the dust from the ailment. Men like wise get breast malignancy, however it is not exceptionally basic. Less than 1% of breast malignancies happen in men. Most breast diseases are found in ladies who are 50 years of age or more seasoned, however breast malignancy additionally influences more youthful ladies. Around 11% of all new instances of breast tumor in the United States are found in ladies more youthful than 45 years old.

INTRODUCTION

Other than skin tumor, breast malignancy is the most widely recognized growth among American ladies. Getting mammograms frequently can bring down the danger of kicking the bucket from breast disease ^[1]. The United States Preventive Services Task Force prescribes that on the off chance that you are 50 to 74 years of age, make certain to have a screening mammogram at regular intervals. In the event that you are 40 to 49 years of age, converse with your specialist about when to begin and how regularly to get a screening mammogram ^[2-5].

Breast Cancer-Symptoms

Diverse individuals have distinctive cautioning signs for breast growth. A few people don't have any signs or side effects by any stretch of the imagination ^[6]. A man may discover they have breast malignancy after a normal mammogram.

Some indications of breast growth are:

- A. New knot in the breast or underarm (armpit)
- B. Thickening or swelling of part of the breast.
- C. Aggravation or dimpling of breast skin
- D. Redness or flaky skin in the areola range or the breast
- E. Pulling in of the areola or agony in the areola territory
- F. Areola release other than breast milk, including blood
- G. Any adjustment in the size or the state of the breast
- H. Torment in any range of the breast.

Remember that some of these notice signs can happen with different conditions that are not malignancy.

Epidemiology

Breast cancer is that the second commonest style of cancer in ladies. Ladies within the USA get carcinoma quite the other style of cancer except carcinoma [7-10]. The amount of latest cases of carcinoma has stayed regarding similar since 2003. Breast Carcinoma is second to carcinoma as a reason behind cancer death in Rank ladies. However, deaths from carcinoma have slashed a trifle bit once a year for the past many years. Carcinoma conjointly happens in men; however, the amount of latest cases is little. White ladies have higher rates of carcinoma compared to different races. This could flow from partly to higher rates of screening for carcinoma in white ladies. In keeping with the National Cancer Institute, 232,340 feminine breast cancers and a pair of 240 male breast cancers square measure rumored within the USA annually, also as regarding thirty-nine,620 deaths caused by the illness. The overwhelming majority of carcinoma cases occur in females [11-15]. This text focuses on carcinoma in ladies. We have a tendency to have a writing regarding male carcinoma.

Breast Cancer Stages

The stage of carcinoma is one among the foremost vital factors in evaluating treatment choices.

1. Stage zero (noninvasive, malignant neoplastic disease in situ) breast cancer: In stage zero, there is no proof of cancer cells breaking out of the part of the breast during which they started, or of obtaining through to or incursive neighboring traditional tissue [16].

2. Stage I breast cancer: In stage I, the neoplasm measures up to 2 centimeters and no body fluid nodes square measure concerned [17].

3. Stage II (invasive) breast cancer: In stage II, the neoplasm measures between 2 to 5 centimeters, or the cancer has unfold to the body fluid nodes underneath the arm on a similar aspect because the carcinoma [18].

4. Stage III (locally advanced) breast cancer: In stage III, the neoplasm within the breast is quite 2 inches in diameter across and therefore the cancer is in depth within the underarm body fluid nodes, or has unfolded to different body fluid nodes or tissues close to the breast [19].

5. Stage IV (metastatic) breast cancer: In stage IV, the cancer has unfold on the far side the breast, underarm and internal exocrine gland body fluid nodes to different elements of the body on the subject of or distant from the breast [20].

6. Continual carcinoma: In continual breast cancer, the illness has come back in spite of the initial treatment.

Types of treatment for breast carcinoma

Radiation medical care

Hormonal medical care

- Radiation medical care (radiotherapy)
- Surgery
- Biological medical care (targeted drug therapy)
- Hormone medical care
- Chemotherapy

DISCUSSION

No breast is run of the mill. What is ordinary for you may not be typical for another lady. Most ladies say their breasts feel knotty or uneven [21-25]. The way your breasts look and feel can be influenced by getting your period, having youngsters, losing or putting on weight, and taking certain meds. Breasts likewise tend to change as you age.

Numerous conditions can bring about knots in the breast, including growth. In any case, most breast bumps are brought about by other restorative conditions. The two most normal reasons for breast knots are fibrocystic breast condition and sores. Fibrocystic condition causes noncancerous changes in the breast that can make them knotty, delicate, and sore. Blisters are little liquid filled sacs that can create in the breast [26]. The principle calculates that impact your danger for breast tumor incorporate being a lady, being more established (most breast growths are found in ladies who are 50 years of age or more seasoned), and having changes in your breast malignancy qualities (BRCA1 and BRCA2). Most ladies who get breast growth have no known danger components and no history of the malady in their families. There are things you can do to can bring down your breast growth hazard [27-30]. The Know:BRCA instrument can help you survey your danger of having changes in your BRCA qualities.

In spite of the fact that breast growth screening can't counteract breast tumor, it can discover breast disease early, when it is less demanding to treat, converse with your specialist about which breast growth screening tests are a good fit for you, and when you ought to have them.

Numerous components through the span of a lifetime can impact your breast disease hazard [31-45]. You can't transform a few elements, for example, getting more seasoned or your family history, yet you can bring down your danger of breast malignancy by dealing with your wellbeing in the accompanying ways—

- A. Keep a solid weight.
- B. Practice frequently (no less than four hours a week).
- C. Research demonstrates that absence of evening rest can be a danger element.
- D. Try not to drink liquor, or breaking point mixed beverages to close to one every day.
- E. Keep away from introduction to chemicals that can bring about growth (cancer-causing agents) and chemicals that meddle with the ordinary capacity of the body.
- F. Limit introduction to radiation from restorative imaging tests like X-beams, CT sweeps, and PET outputs if not therapeutically fundamental.
- G. In the event that you are taking, or have been advised to take, hormone substitution treatment or oral contraceptives (conception prevention pills), get some information about the dangers and see whether it is a good fit for you.

BREAST CANCER SCREENING RECOMMENDATIONS

The United States Preventive Services Task Force (USPSTF) is an association made up of specialists and illness specialists who take a gander at exploration on the most ideal approach to anticipate maladies and make suggestions on how specialists can help patients stay away from ailments or discover them early [46-58].

The USPSTF prescribes those ladies who are 50 to 74 years of age and are at normal danger for breast disease get a mammogram at regular intervals [58-65]. Ladies who are 40 to 49 years of age ought to converse with their specialist or other social insurance proficient about when to begin and how regularly to get a mammogram. Ladies ought to measure the advantages and dangers of screening tests when choosing whether to start getting mammograms at age 40 [66-78].

Breast Cancer Screening Tests

Mammogram: A mammogram is X-beam of the breast. Mammograms are the most ideal approach to discover breast growth early, when it is less demanding to treat and before it is sufficiently enormous to feel or cause side effects [79,80]. Having normal mammograms can bring down the danger of kicking the bucket from breast malignancy.

Breast magnetic resonance imaging (MRI): A breast MRI utilizes magnets and radio waves to take photos of the breast. X-ray is utilized alongside mammograms to screen ladies who are at high hazard for getting breast growth [81-90]. Since breast MRIs may seem unusual notwithstanding when there is no growth, it is not utilized for ladies at normal danger. You can get screened for breast tumor at a center, doctor's facility, or specialist's office. On the off chance that you need to be screened for breast disease, call your specialist's office. They can help you plan an arrangement. Most medical coverage arrangements are required to cover mammograms each one to two years for ladies starting at age 40 with no out-of-pocket cost (like a co-pay, deductible, or co-protection) [91-100].

CONCLUSION

Every year in the United States, more than 200,000 women get breast growth and more than 40,000 women bite the dust from the ailment. Men likewise get breast malignancy, however it is not exceptionally basic.

Less than 1% of breast malignancies happen in men. Most breast diseases are found in women who are 50 years of age or more seasoned, however breast malignancy additionally influences more youthful ladies. Around 11% of all new instances of breast tumor in the United States are found in women more youthful than 45 years old.

REFERENCES

1. Târcoveanu E, et al. Particularities of Primary Breast Cancer in Men. *J Surg.* 2016;12:29-35.
2. Trinh KX, et al. A Novel Anti-tumor Protein from Calloselasma Rhodostoma Venom in Vietnam. *Anat Physiol.* 6:213.
3. Bordag N, et al. Fast Sampling of Adherent Cell Cultures for Optimal Metabolomics Results. *Metabolomics.*2016;6:164.
4. Aydin AS, et al. A Rare Case of Primary Breast Cancer with Isolated Renal Parenchymal Metastasis Mimicking Primary Renal Cell Carcinoma. *J Clin Case Rep.*2016;6:724.
5. Pucci-Minafra I, et al. Proteomic Profiling of In-Vitro Bone-Conditioned SKBR3 Breast Cancer Cells. *J Proteomics Bioinform.* 2016;9:075-083.
6. Maeno K, et al. Significance of Sentinel Lymph Nodes with Low Gamma Counts in Breast Cancer Patients via Radioisotopic Sentinel Lymph Node Biopsy. *Arch Surg Oncol.* 2016;2:109.
7. Moses SL, et al. Cytotoxicity in MCF-7 and MDA-MB-231 Breast Cancer Cells, without Harming MCF-10A Healthy Cells. *J Nanomed Nanotechnol.* 2016;7:369.
8. Dogan S, et al. The Detection of Extremely High and Low Expressed Genes by EGEF Algorithm in Invasive Breast Cancer. *J Biom Biostat.* 2016;7:286.
9. Gayatri Devi V, et al. Therapeutic Potentials of CD151 shRNA in Targeting Metastasis of Triple Negative Breast Cancer Cell Line MDA-MB-231. *J Cancer Sci Ther.* 2016;8:104-112.
10. Ofor O, et al. CTCF May Not Directly Regulate ER α mRNA Expression in the ER+ MCF7 Breast Cancer Cell Line. *J Cancer Sci Ther.* 2016;8:059-065.
11. Dehbid M, et al. Evaluation of DNA Methylation of MAP9 Gene in Breast Cancer as Epigenetic Biomarker. *J Mol Biomarkers Diagn.* 2016;S8:015.
12. Osman U and Gilbert CR. Bronchial Necrosis Following Bevacizumab and Stereotactic Body Radiotherapy for Treatment of Metastatic Breast Cancer. *J Pulm Respir Med.* 2016;6:345.
13. Shahbazi S, et al. Semiempirical Investigation of the Postmenopausal Breast Cancer Treatment Potential of Xanthone Derivatives. *Nat Prod Chem.* 2016;4:206.
14. Ondimu TO, Factors that Influence the Uptake of Breast Cancer Screening among Secondary School Student: Case of Kisii South Sub-County Kenya. *Oncol Cancer Case Rep.*2016;1:109.
15. Colone M, et al. Redox-active Microcapsules as Drug Delivery System in Breast Cancer Cells and Spheroids. *J Mol Genet Med.* 2016;10:200.
16. Grech G, et al. Molecular Classification of Breast Cancer Patients using Formalin-Fixed Paraffin-Embedded derived RNA Samples. *J Mol Biomarkers Diagn.* 2016;7:S8-016.
17. Álvarez-Bañuelos MT, et al. Prognostic Factors Associated with Survival in Women with Breast Cancer from Veracruz, Mexico. *J Cancer Sci Ther.* 2016;8:092-098.
18. Bila A and Gramatiuk S. To Compare the Mitochondrial Complex between Metastasis Breast Cancer and Patients with Breast Cancer and Hepatitis C Virus. *J Women's Health Care.* 2016;5:315.
19. Smichkoska S and Lazarova E. Long Term Trastuzumab in Metastatic Setting of the Patients with HER2 Positive Breast Cancer. *J Blood Lymph.* 2016;1:103.
20. El-Lathy HA, et al. The Impact of Pretreatment 18F-FDG (PET/CT) Maximum Standardized Uptake Value and Neutrophil/Lymphocyte Ratio (NLR) in Predicting Prognosis in Surgically Treated Oligometastatic Breast Cancer Patients. *J Nucl Med Radiat Ther.* 2015;7:271.
21. Grondona JP, et al. Hepatic Resection for Breast Cancer Liver Metastases. *J Cancer Clin Trials.* 2016;1:110.
22. Li T. Combination of Nab-Paclitaxel with Trastuzumab as Neoadjuvant Chemotherapy for HER2-positive Breast Cancer Patients: Experience from a Single Center. *Clin Exp Pharmacol.* 2016;6:209.
23. Anderson J. Updates in the Use of the mTOR Inhibitor Everolimus in Advanced Breast Cancer. *J Cancer Clin Trials.* 2016;1:111
24. Hussain SM. Immunohistochemical Expression of Cyclin D1 in Human Breast Carcinoma. *J Integr Oncol.* 2016;S1:003.

25. Sandra SH. Pleomorphic Lobular Carcinoma of the Breast: A Review of 35 Cases at a Single Institution. *Breast Can Curr Res*. 2016;1:105.
26. Rios SSD. Wearing a Tight Bra for Many Hours a Day is Associated with Increased Risk of Breast Cancer. *Adv Oncol Res Treat*. 2016;1:105.
27. Mizejewski GJ. Does Elevated Alpha-fetoprotein During Pregnancy Protect Against Breast Cancer Later in Life? A Commentary. *Anat Physiol*. 2016;6:e139.
28. Olaya N. Bovine Leukemia: Zoonosis Associated with Breast Cancer in Humans?. *J Med Surg Pathol*. 2016.
29. Lucibello M. Phospho-TCTP and Dihydroartemisinin: A Novel Therapeutic Opportunity in Advance Breast Cancer. *Chemo Open Access*. 2016;5:196.
30. Akihiko Osaki. Adjuvant Chemotherapy with S-1 in Breast Cancer Patients after Primary Systemic Chemotherapy. *Chemo Open Access*. 2016;5:187.
31. Heidari A. A Chemotherapeutic and Biospectroscopic Investigation of the Interaction of Double-Standard DNA/RNA-Binding Molecules with Cadmium Oxide (CdO) and Rhodium (III) Oxide (Rh2O3) Nanoparticles as Anti-Cancer Drugs for Cancer Cells' Treatment. *Chemo Open Access*. 2016;5:e129.
32. Principe M, et al. Blockade of Surface Alpha-Enolase (ENO1) as a Novel Immunotherapeutic Approach in Pancreatic Cancer. *Chemo Open Access*. 2016;5:188.
33. Bagella L, et al. SFK Inhibitors as New Strategy for RMS Treatment. *Chemo Open Access*. 2016;5:189.
34. Zhang M, et al. Targeting Human β -Microglobulin with Monoclonal Antibodies in Multiple Myeloma - A Potential in Treatment. *Chemo Open Access*. 2016;5:190.
35. Di Agostino S, et al. Genomic Instability: The Pivotal Role of Mutant p53 in Human Cancers. *Chemo Open Access*. 2016;5:191.
36. Wang Y, et al. Raltitrexed based Transcatheter Arterial Chemoembolization (TACE) for Unresectable Hepatocellular Carcinoma: A Single-center Randomized Controlled Study. *Chemo Open Access* 2016 ;5:192.
37. Cheng H, et al. A New Mutation Identified in an Imatinib and Nilotinib Resistant Chronic Myeloid Leukemia Patient. *Chemo Open Access*. 2016;5:193.
38. Ullah E, et al. Prognostic Role of Microvascular Density and Mucin Production in 56 Cases of Adenocarcinoma of Lung- An Experience from a Center in Lahore, Pakistan. *Chemo Open Access*. 2016;5:194.
39. Zhu M, et al. Alpha Fetoprotein Plays Antagonistic Role in Benzyl-Isothiocyanate Arresting Cell Cycle in Liver Cancer Cells. *Chemo Open Access*. 2016;5:195.
40. Lucibello M and De Braud F. Phospho-TCTP and Dihydroartemisinin: A Novel Therapeutic Opportunity in Advance Breast Cancer. *Chemo Open Access*. 2016;5:196.
41. Kubo A, et al. NK-1 Receptor Antagonists: Who Truly Need them and their Cost- Effectiveness Analysis?. *Chemo Open Access*. 2016;5:197.
42. Fedele M, et al. The Tumor Suppressive Role of PATZ1 in Thyroid Cancer: A Matter of Epithelial-Mesenchymal Transition. *Chemo Open Access*. 2016;5:198.
43. Dong J, et al. Targeting ROS for Cancer Therapy. *Chemo Open Access*. 2016;5:199.
44. Zhu HH, et al. CD34-Negative is Highly Associated with T (15;17), T (V;11q23) and the NPM1-Mutation Subtypes in 343 Newly Diagnosed Patients with Acute Myeloid Leukemia . *Chemo Open Access*. 2016;5:200.
45. Yang H, et al. FBXW7 Pathway Functions as a Promising Therapeutic Target of Cholangiocarcinoma. *Chemo Open Access*. 2015;5:201.
46. Jyoti BS. Accuracy of MRI for Prediction of Response to Neo-Adjuvant Chemotherapy in Triple Negative Breast Cancer Compared to Other Molecular Types. *Chemo Open Access*. 2015;5:175.
47. Cheng Liu. Limb Salvage Strategy by Intra-Arterial Chemotherapy for Local Recurrent Osteosarcoma in Extremities. *Chemo Open Access*. 2015;5:176.
48. Christos K. Follow up of Testicular Tumours for How Long it is Necessary?. *Chemo Open Access*. 2015;5:177.
49. Sharma and Cheng. New & Emerging Drugs for Squamous Cell Lung Cancer. *Chemo Open Access*. 2015;5:178.
50. De Domenico EBL, et al. Professional Competence in Oncology: Challenges for Education . *Chemo Open Access*. 2015;5:179.
51. Niang M, et al. Biochemical and Pharmacological Effects of Mitoxantrone and Acetyl-L-Carnitine in Mice with a Solid Form of Ehrlich Tumour. *Chemo Open Access*. 2015;5:180.
52. Soldà C, et al. Good and Prolonged Response to Low Dose Capecitabine as Second Line Therapy in a Patient with Advanced Hepatocellular Carcinoma. *Chemo Open Access*. 2015;5:181.

53. Xu M, et al. Aggressive Natural Killer Cell Leukemia Secondary to Hodgkin Lymphoma: a Case Report and Review of the Literature. *Chemo Open Access*. 2016;5:182.
54. Provenzano M and Xavier Keller E. The Potential Therapeutic Usefulness of Targeting BK Polyomavirus in Prostate Cancer. *Chemo Open Access*. 2015;5:184.
55. Chen Y and Wan X. Lmdd-MPPG Prevents HCC Occurrence through Dendritic Cells Related Signaling Pathways. *Chemo Open Access*. 2016;5:185.
56. Wang YM, et al. A Study Design: Concurrent EGFR-TKI and Thoracic Radiotherapy as First line Treatment of Stage IV NSCLC Patients with EGFR Active Mutations (CERTAIN Study). *Chemo Open Access*. 2016;5:186.
57. Akihiko Osaki. Adjuvant Chemotherapy with S-1 in Breast Cancer Patients after Primary Systemic Chemotherapy. *Chemo Open Access*. 2016;5:187.
58. Rahmani S, et al. The Clinical and Histopathological Significance of Performing Surgical Cavity Random Biopsy in Breast Conserving Surgery on Disease Course and Local Recurrence. *Breast Can Curr Res*. 2016;1:104.
59. Sandra SH, et al. Pleomorphic Lobular Carcinoma of the Breast: A Review of 35 Cases at a Single Institution. *Breast Can Curr Res*. 2016;1:105.
60. Meredith I, et al. Mammographic Surveillance after Breast Reconstruction-Is Imaging Necessary?. *Breast Can Curr Res*. 2016;1:106.
61. Kinoshita S, et al. Clinicopathological Assessment of Patients with Locally Advanced Breast Cancer with 10 or More Lymph Node Metastases. *Breast Can Curr Res*. 2016;1:107.
62. Aymen FA, et al. Axillary Masse, is it an Ectopic Mammary Gland?. *Breast Can Curr Res*. 2016;1:108.
63. Carmichael AR, et al. What is the Impact of Lifestyle on the Incidence of Cancer? *J Blood Lymph*. 2015;1:e101.
64. Andres Gomez .The Mammi Breast Pet. A New Weapon for the Diagnosis of Breast Cancer. *J Blood Lymph*. 2015;1:e102.
65. Singh A and Arora D. A Case of Breast Cancer Recurrence at the "Match Line". *J Blood Lymph*. 2015;1:101.
66. Khawaja S, et al. A Comparison Between Oncoplastic Breast Conserving Surgery and Standard Wide Local Excision: A UK Experience. *J Blood Lymph*. 2015;1:102.
67. Smichkoska S and Lazarova E. Long Term Trastuzumab in Metastatic Setting of the Patients with HER2 Positive Breast Cancer. *J Blood Lymph*. 2016;1:103.
68. Becerra-Torres SL and Castillo-Hernández L . The Neurotoxic Effects of 2-Nitropropane on Nerve Conduction are Reversible. *In Vitro Chemotherapy*. 2012;1:101.
69. Becerra-Torres SL and Castillo-Hernández L. Effect of 2-Nitropropane on Chemical Neurotransmission, Spontaneous and Evoked, in the Sartorius Muscle of the Frog. *Chemotherapy*. 2012;1:102.
70. Figueiró Longo JP, et al. Effects of Photodynamic Therapy Mediated by Liposomal Aluminum-phthalocyanine Chloride on Chemically Induced Tongue Tumors. *Chemotherapy*. 2012;1:103.
71. Maiti AK. Reactive Oxygen Species Reduction is a Key Underlying Mechanism of Drug Resistance in Cancer Chemotherapy. *Chemotherapy*. 2012;1:104.
72. Dobashi Y, et al. Molecularly Targeted Therapy: Past, Present and Future. *Chemotherapy*. 2012;1:105.
73. Loth K, et al. Infectious Complications Associated with the Use of Antithymocyte Globulin in Reduced Intensity Allogeneic Transplants. *Chemotherapy*. 2012;1:106.
74. Zhang B, et al. A Potential Administration-time Dependent Effect of Bevacizumab in Improving Overall Survival and Increasing Metastasis in Metastatic Colorectal Cancer. *Chemotherapy*. 2013;2:108.
75. Chase DM, et al. Updates on Anti-Cancer Therapy in Ovarian Cancer. *Chemotherapy*. 2013;2:109.
76. Polenz C, et al. Adjuvant Chemotherapy for Colorectal Cancer – Timing is Everything. *Chemotherapy*. 2013;2:110.
77. Lee J and Huang R .Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, Vorinostat. *Chemotherapy*. 2013;2:111.
78. Pandey V, et al. Vincristine Induced Isolated Bilateral Ptosis in a Child with Wilms' Tumour: Case Report with Review of Literature. *Chemotherapy*. 2013;2:112.
79. Angioli R, et al. Liposome Encapsulated Doxorubicin Citrate (Ledc) as an Alternative Therapeutic Option for Patients with Recurrent Ovarian Cancer Suffering from Doxorubicin-Related Cutaneous Toxicity. *Chemotherapy*. 2013;2:113.
80. Mao L, et al. The First Case of Decitabine Successfully in Treatment of Atypical Chronic Myeloid Leukemia with CEBPA Double Mutation. *Chemotherapy*. 2013;2:114.

81. Shabana MM, et al. In Vitro and In Vivo Anticancer Activity of the Fruit Peels of Solanum melongena L. against Hepatocellular Carcinoma. *J Carcinogene Mutagene*. 2013;4:149.
82. Rea MS and Figueiro MG . A Working Threshold for Acute Nocturnal Melatonin Suppression from “White” Light Sources used in Architectural Applications. *J Carcinogene Mutagene*. 2013;4:150.
83. Said N and Theodorescu D . Secreted Protein Acidic and Rich in Cysteine (Sparc) in Cancer. *J Carcinogene Mutagene*. 2013;4:15.
84. Klein C .Chemotherapeutics - Where to Now? *Chemotherapy*. 2012;1:e101.
85. Maiti AK. Why “Chemotherapy” Should be an Open Access Journal. *Chemotherapy*. 2012;1:e102.
86. Wu J. Predictive Biomarkers to Therapy, do they Exist in Hepatocellular Carcinoma? *Chemotherapy*. 2012;1:e104.
87. Becerra-Torres SL and Castillo-Hernández L. The Neurotoxic Effects of 2-Nitropropane on Nerve Conduction are Reversible, In Vitro. *Chemotherapy*. 2012;1:101.
88. Maiti AK. Ethnic Population Specific Drug Design. *Chemotherapy*. 2012;1:e103.
89. Wagenlehner FME. Do We Need PK/PD in the Treatment of Urogenital Infections? *Chemotherapy*. 2012;1:e105.
90. Pliquett U. Electrochemotherapy – A New Way for Enhancing Cancer Treatment. *Chemotherapy*. 2012;1:e106.
91. Maiti AK. Reactive Oxygen Species Reduction is a Key Underlying Mechanism of Drug Resistance in Cancer Chemotherapy. *Chemotherapy*. 2012;1:104.
92. Konishi T. Complimentary Use of Antioxidant Dietary Factor is Promised in Cancer Treatment. *Chemotherapy*. 2012;1:e107.
93. Putz G . Dosing of Chemotherapeutic Drugs –Time to Leave the Stone Age. *Chemotherapy*. 2012;1:e108.
94. Johanning GL. Stapled Peptides as Anti-Apoptotic Drugs. *Chemotherapy*. 2012;1:e109.
95. Wang J and Talmadge JE .Targeting Tumor-Related Immunosuppression using Metronomic Cyclophosphamide in Combination with Lenalidomide -New Mechanisms for Old Drugs. *Chemotherapy*. 2012;1:e110.
96. Tu SM. Origin of Cancers: Gene-Centric Versus Cell-Centric. *Chemotherapy*. 2012;1:e111.
97. Muehlmann LA and de Azevedo RB. On How Could Light and Nanostructures Lead the Way to a Safer Anticancer Therapy. *Chemotherapy*. 2012;1:e112.
98. Dobashi Y. Molecularly Targeted Therapy: Great Progress or Evil Cycle. *Chemotherapy*. 2012;1:e113.
99. Yan M .Cancer Chemotherapy and Cancer Personalized Medicine: An Old Car with a New Engine. *Chemotherapy*. 2012;1:e114.
100. Grivennikov SI, et al. Immunity, inflammation, and cancer. *Cell*. 2010;140:883–899.
101. Oyesanmi O, et al. Alcohol Consumption and Cancer Risk: Understanding Possible Causal Mechanisms for Breast and Colorectal Cancers. Rockville:Agency for Healthcare Research and Quality, U.S. Dept. of Health and Human Services;2010.
102. Zhong Q, et al. Alteration of BRCA1 expression affects alcohol-induced transcription of RNA Pol III-dependent genes. *Gene*. 2015;556:74–79.
103. Xu M, et al. Cyanidin-3-glucoside inhibits ethanol-induced invasion of breast cancer cells overexpressing ErbB2. *Mol Cancer*. 2010;9:285.
104. Wang L, et al. Ethanol enhances tumor angiogenesis in vitro induced by low-dose arsenic in colon cancer cells through hypoxia-inducible factor 1 alpha pathway. *Toxicol Sci*. 2012;130:269–280.
105. Xu M, et al. Ethanol disrupts vascular endothelial barrier: implication in cancer metastasis. *Toxicol Sci*. 2012;127:42–53.
106. Goldberg JE. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. *Curr Drug Targets*. 2010;11:1133–1146.
107. Carballo M, et al. Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear translocation in human lymphocytes. *J Biol Chem*. 1999;274:17580–17586.
108. Xiong A, et al. Transcription factor STAT3 as a novel molecular target for cancer prevention. *Cancers (Basel)*. 2014;6:926–957.
109. Posa JK, et al. p53 mediates impaired insulin signaling in 3T3-L1 adipocytes during hyperinsulinemia. *Cell Biol Int*. 2014;38:818–824.
110. Sangeetha KN, et al. 3Beta-taraxerol of *Mangifera indica*, a PI3K dependent dual activator of glucose transport and glycogen synthesis in 3T3-L1 adipocytes. *Biochim Biophys Acta*. 2010;1800:359–366.

111. Shilpa K, et al. Probing key targets in insulin signaling and adipogenesis using a methanolic extract of *Costus pictus* and its bioactive molecule, methyl tetracosanoate. *Biotechnol Lett.* 2009;31:1837–1841.
112. Wong AW, et al. Alcohol promotes breast cancer cell invasion by regulating the Nm23-ITGA5 pathway. *J Exp Clin Cancer Res.* 2011;30:75.
113. Hong J, et al. Alcohol consumption promotes mammary tumor growth and insulin sensitivity. *Cancer Lett.* 2010;294:229–235.
114. Bishop JL, et al. The multifaceted roles of STAT3 signaling in the progression of prostate cancer. *Cancers (Basel).* 2014;6:829–859.
115. Seitz HK. Alcohol and breast cancer. *Breast.* 2012;21:426–427.
116. Wagner F, et al. Ethanol inhibits interferon-gamma secretion by human peripheral lymphocytes. *J Stud Alcohol.* 1992;53:277–280.
117. Long XE, et al. Suppression of CDK2 expression by siRNA induces cell cycle arrest and cell proliferation inhibition in human cancer cells. *BMB Rep.* 2010;43:291–296.
118. Berthet C, et al. Cdk2 and Cdk4 cooperatively control the expression of Cdc2. *Cell Div.* 2006;1:10.
119. Wu J, et al. MicroRNA-188 suppresses G1/S transition by targeting multiple cyclin/CDK complexes. *Cell Commun Signal.* 2014;12:66.